Royalty Report: Drugs, Cancer, Disease – Collection: 3789

License Grant

The Company entered into an agreement with Licensee, the former Board of Directors and as the Company’s President and Chief Scientific Officer, for certain patents regarding the molecular diagnostic technology platforms.

License Property

The patents cover highly predictive, metastic cancer molecular diagnostic test products, including the EP-CAM Detection Kit(TM).

These patents related to a proprietary technological product for the detection of epithelial cancer, referred to as the “EP-CAM Detection Kit.”

As a result of an acquisition, the Company now owns the rights to the following two (2) Greek patents and four (4) Greek patent applications
Greek Patent No. 1004303, issued November 6, 2002, entitled “Detection of cancer membrane antigen Ep-Cam and identification of circulating micrometastatic cancer cells in peripheral blood (and tissues) in patients with cancer of epithelial origin.”
Greek Patent No. 1004765, issued December 22, 2004 – PCT-Pending, entitled “Detection of cancer membrane antigen Ep-Cam and identification of circulating micrometastatic cancer cells in peripheral blood (and tissues) in patients with cancer of epithelial origin.”
Greek Patent Application No. 20040100269, dated July 2, 2004, entitled “Prototype RT and PCR protocols using Neowater and detection of cancer membrane antigen Ep-Cam and identification of circulating micrometastatic cancer cells in peripheral blood (and tissues) in patients with cancer of epithelial origin.”

License Grant

The University grants an exclusive license under the patents and technology to use, have used, manufacture, have manufactured, sell and/or have sold licensed products within the licensed territory and licensed field.

License Property

The licensed patents and technology are for methods and reagents for detecting and characterizing carcinoma cells in the blood.

The technology licensed relates to the isolation, enrichment and characterization of circulating epithelial cells. Epithelial cells are cells that cover external and internal body surfaces and give rise to the majority of solid tumors. This technology and the underlying patents and know-how contribute significantly to the Licensee's cell analysis products in the field of cancer diagnostics.

1. U.S. Provisional Patent Application Serial Number 60/074,535, filed February 12, 1998, entitled 'Test For Detecting, Enumerating and Characterizing Carcinoma Cells in the Blood' (corresponding for reference purposes only to UT SOUTHWESTERN file number UTSD568-PZ1).

2. U.S. Provisional Patent Application Serial Number 60/110,202, filed November 30, 1998, entitled 'Detection and Characterization of Carcinoma Cells in the Blood' (corresponding for reference purposes only to UT SOUTHWESTERN file number UTSD568-PZ2).

3. U.S. Patent Application Serial Number 09/248,388, filed February 12, 1999, entitled 'Methods and Reagents for the Rapid and Efficient Isolation of Circulating Cancer Cells' (corresponding for reference purposes only to UT SOUTHWESTERN file number UTSD568).

Field of Use

The Licensed Field means isolation, enrichment and characterization of circulating epithelial cells, and determination of their relationship to cancer disease states.

License Grant

Licensor hereby grants the right to use MoAb 7E11-C.5.3 solely for such purposes.

License Property

The term 'MoAb 7E11 shall mean and collectively include that certain antibody to PSMA known as MoAb 7E11-C5, which such antibody is claimed in United States Patent No 5,162,504, granted November 10, 1992, and entitled 'Monoclonal Antibodies to a New Antigenic Marker in Epithelial Prostatic Cells and Serum of Prostate Cancer Patients.'  One subclone of MoAb 7E11 is MoAb 7E11-C5.3.  To enable the licensee to utilize MoAb 7E11-C 5.3 in connection with the development, manufacturing, testing, or conducting quality control tests on Licensed Products and to practice Licensed Processes.

Field of Use

The term 'PSMA' shall mean prostate specific membrane antigen and shall include the PSMA protein.

The term 'PSMP' shall mean prostate specific membrane peptides which shall include any peptide sequence appearing within the PSMA protein.

The term 'Licensed Products' shall mean products for the immunotherapy of prostate cancer which are produced by [  ***  ], with a composition including PSMA and/or PSMP, and/or the mimetopes of PSMA or PSMP.

The term 'Licensed Processes' shall mean any process for the immunotherapy of prostate cancer in patients by [  ***  ] including, but not limited to [  ***  ], ex vivo, with a composition including PSMA and/or PSMP, and/or the mimetopes of PSMA or PSMP, and [  ***  ] the use or practice of which would, but for the licenses granted herein, infringe one or more Valid Claims of an issued patent or pending patent application included in SKICR Patent Rights.

License Grant

The Company grants an exclusive, worldwide, royalty-bearing License, with the right to subLicense, to make, have made, use, sell and import Licensed Products, which includes finished products used for the detection of the Company’s proprietary prostate cancer biomarkers in both urine and biopsied prostate tissue for differentiating clinically significant prostate cancer from other prostate conditions, and to use Patent Rights and Know-How covering the prostate cancer biomarkers.

License Property

Licensed Product(s) shall mean finished products consisting of one or more nucleic acid detection reagents for the assay of one or more Prostate Marker(s) for use in the Field, the manufacture, use, sale or importation of which, but for the rights granted herein, would infringe a Valid Claim within Patent Rights.

U.S.
7,117,188
Method of Identifying Patterns in Biological Systems and Uses Thereof

U.S.
12/025,724
Biomarkers Upregulated in Prostate Cancer

U.S.
12/242,264
Biomarkers Overexpressed in Prostate Cancer

U.S.
12/327,823
Methods for Screening, Predicting and Monitoring Prostate Cancer

U.S.
12/349,437
Methods for Screening, Predicting and Monitoring Prostate Cancer

Field of Use

Field shall mean the use of a molecular diagnostic assay using the Licensed Prostate Markers in in vitro diagnostics relating to prostate cancer, including the detection of the presence or risk of prostate cancer, or the selection of therapy, or in a Research Application related to prostate cancer.

License Grant

Licensor, an individual, of United Kingdom grants, and Licensee of Taiwan accepts, an exclusive license to the Licensed Technology on a royalty-bearing basis for revenue-generating Authorized Uses in the Field of Use in the Licensed Territory. Licensee may not sell Licensed Technology to a third-party or seek patent protection for Licensed Technology. In order to ensure that Licensee can use the license, Licensor will use his best efforts to provide ongoing technical assistance in order for Licensee to perfect the Licensed Technology.

License Property

Licensor owns all rights, title, and interest in United States patent and pending patent applications along with related foreign patent applications, specified and referenced herein as U.S. Patent No. 6,743,593 (593 patent); U.S. Patent Application Serial No. 10/612,818 filed on July 1, 2003, which is a continuation-in-part application of the `593 patent; International Application No. PCT/US01/11233; International Application No. PCT/US03/20887; China Patent Application No. 01810709.5; and India Patent Application No. IN/PCT/2002/00998/DEL;

Licensed Technology shall mean United States Patent No. 6,743,593, pending United States Patent Application Serial No. 10/612,818 filed on July 1, 2003; International Application No. PCT/US01/11233 and International Application No. PCT/US03/20887; China Patent Application No. 01810709.5; and India Patent Application No. ___________.

Field of Use

Field of Use shall mean use of sequences disclosed in Licensed Technology for use in the sale of a human diagnostic test for cervical cancer.

License Grant

The German Licensor grants the Swiss Licensee a worldwide, exclusive, right and license, or sublicense, with the right to grant sublicenses, under the Licensed Technology to make, have made, use, offer for sale, sell, and import the Product in the Field in the Territory.

This agreement includes a non-exclusive grant by Licensee to Licensor.

License Property

Licensor is developing a pharmaceutical product comprising a human antibody of IgG-1 subtype binding to EpCAM.

The patents include Novel Method for the Production of anti-human Antigen Receptors and Uses thereof, and, Anti-EpCAM Immunoglobulins.

Decatumumab (MT201) is a recombinant human monoclonal antibody with a binding specificity to epithelial cell adhesion molecule (Ep-CAM). Adecatumumab (MT201) is being evaluated in two European Phase 2 clinical trials, one in patients with prostate cancer, and one in patients with metastatic breast cancer.

Field of Use

The Field means the treatment of human diseases, disorders and conditions.